Medical Educational Resource
We're accelerating the delivery of treatments and cures.
The CIFFREO Study
Activity Snapshot
Activity Type:
On-Demand Webinar
Release Date:
Tuesday, July 5, 2022
Sponsor Information:
This Industry Update Webinar is sponsored by Pfizer. This program is not sponsored, endorsed, or accredited by MDA.
Faculty
Kasia Lobello, MD
Global Clinical Lead
Duchenne Muscular Dystrophy Gene Therapy Program Pfizer
Activity Overview:
This Industry Update Webinar for clinicians is presented by Pfizer and features information on the CIFFREO study. On June 15, 2022 at 12:00PM EST in a 30-minutes webinar, Dr. Kasia Labello, Global Clinical Lead for the Duchenne Muscular Dystrophy Gene Therapy Program at Pfizer, provided an overview of the CIFFREO study. The CIFFREO Study is a Phase 3, Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of mini-dystrophin Gene Therapy (fordadistrogene movaparvovec) in Ambulatory Boys with DMD.
